Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Novocure (NASDAQ: NVCR) will host a virtual Research & Development Day on November 12, 2020, from 7:30 a.m. to 9:30 a.m. EDT. This event aims to showcase advancements in its clinical and product development pipelines, featuring presentations from Novocure's research teams and prominent scientists focused on Tumor Treating Fields. Attendees can access the live webcast on Novocure's Investor Relations page, with a replay available for 14 days afterward. Novocure is dedicated to treating aggressive cancers through innovative therapies, including ongoing trials for various cancer types.